Welcome to our dedicated page for Neuraxis news (Ticker: NRXS), a resource for investors and traders seeking the latest updates and insights on Neuraxis stock.
Neuraxis Inc (NRXS) pioneers neuromodulation therapies targeting pediatric gut-brain disorders through its FDA-cleared IB-Stim® technology. This hub provides investors and medical professionals with essential updates on clinical advancements, regulatory developments, and strategic initiatives driving innovation in neurogastroenterology.
Access timely press releases covering pivotal milestones including clinical trial outcomes, partnership announcements, and peer-reviewed research publications. Our curated news collection enables efficient tracking of the company’s evidence-based approach to treating functional abdominal pain and related conditions in pediatric populations.
Key updates about PENFS technology applications, intellectual property developments, and healthcare collaborations are maintained here for due diligence and market analysis. Bookmark this page to monitor NRXS’s progress in advancing non-pharmacological solutions for chronic gut-brain interaction disorders.
NeurAxis announced the expansion of medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) through a Blue Cross Blue Shield (BCBS) licensee in Florida. This new policy covers nearly six million members, increasing the total coverage for IB-Stim to approximately 22.5 million lives. IB-Stim™ is a non-surgical device FDA-cleared for treating functional abdominal pain linked to irritable bowel syndrome (IBS) in adolescents. The expansion aligns with NeurAxis' commercialization strategy and is expected to boost market adoption and revenue growth.
NeurAxis (NRXS), a medical technology company specializing in neuromodulation therapies for chronic conditions, will release its Q1 2024 financial results on May 22, 2024, before market open. The period covered is up to March 31, 2024. A conference call is scheduled for the same day at 9:00 am ET to review the results. NeurAxis has also filed a Form 12b-25, indicating a delay in filing its Form 10-Q, which is now expected to be filed on May 20, 2024.
The conference call can be accessed via a live webcast available in the Investor Relations section of NeurAxis' website, and replay options will be provided. Participants can submit questions through the webcast portal or by emailing NRXS@lythampartners.com.
FAQ
What is the current stock price of Neuraxis (NRXS)?
What is the market cap of Neuraxis (NRXS)?
